215 related articles for article (PubMed ID: 20877299)
1. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.
Fleeman N; Dundar Y; Dickson R; Jorgensen A; Pushpakom S; McLeod C; Pirmohamed M; Walley T
Pharmacogenomics J; 2011 Feb; 11(1):1-14. PubMed ID: 20877299
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
Dahl ML
Clin Pharmacokinet; 2002; 41(7):453-70. PubMed ID: 12083975
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.
Fleeman N; McLeod C; Bagust A; Beale S; Boland A; Dundar Y; Jorgensen A; Payne K; Pirmohamed M; Pushpakom S; Walley T; de Warren-Penny P; Dickson R
Health Technol Assess; 2010 Jan; 14(3):1-157, iii. PubMed ID: 20031087
[TBL] [Abstract][Full Text] [Related]
4. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.
Mihaljević-Peles A; Sagud M; Bozina N; Zivković M; Jovanović N
Psychiatr Danub; 2010 Jun; 22(2):335-7. PubMed ID: 20562776
[TBL] [Abstract][Full Text] [Related]
6. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment.
van de Bilt MT; Prado CM; Ojopi EP; Sousa RT; Loch AA; Zanetti MV; Talib LL; Gattaz WF
Schizophr Res; 2015 Oct; 168(1-2):587-8. PubMed ID: 26298540
[TBL] [Abstract][Full Text] [Related]
8. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
[TBL] [Abstract][Full Text] [Related]
9. Personalized antipsychotic treatment: the adverse effects perspectives.
Plesnicar BK
Psychiatr Danub; 2010 Jun; 22(2):329-34. PubMed ID: 20562775
[TBL] [Abstract][Full Text] [Related]
10. [Clinical pharmacogenetics in the treatment of schizophrenia].
Saito M; Yasui-Furukori N; Kaneko S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):129-35. PubMed ID: 16045195
[TBL] [Abstract][Full Text] [Related]
11. CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence.
Ravyn D; Ravyn V; Lowney R; Nasrallah HA
Schizophr Res; 2013 Sep; 149(1-3):1-14. PubMed ID: 23870808
[TBL] [Abstract][Full Text] [Related]
12. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.
Dorado P; Peñas-Lledó EM; Llerena A
Pharmacogenomics; 2007 Nov; 8(11):1597-608. PubMed ID: 18034624
[TBL] [Abstract][Full Text] [Related]
14. Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial.
Jürgens G; Andersen SE; Rasmussen HB; Werge T; Jensen HD; Kaas-Hansen BS; Nordentoft M
JAMA Netw Open; 2020 Dec; 3(12):e2027909. PubMed ID: 33284338
[TBL] [Abstract][Full Text] [Related]
15. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants.
Sjöqvist F; Eliasson E
Clin Pharmacol Ther; 2007 Jun; 81(6):899-902. PubMed ID: 17392719
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of classical and new antipsychotic drugs.
Otani K; Aoshima T
Ther Drug Monit; 2000 Feb; 22(1):118-21. PubMed ID: 10688273
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.
Scordo MG; Spina E; Romeo P; Dahl ML; Bertilsson L; Johansson I; Sjöqvist F
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):679-83. PubMed ID: 11214775
[TBL] [Abstract][Full Text] [Related]
18. CYP 2D6 polymorphism and antipsychotic therapy.
Plesnicar BK; Dolzan V; Zalar B
Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 mutations and therapeutic outcome in schizophrenic patients.
Hamelin BA; Dorson PG; Pabis D; Still D; Bouchard RH; Pourcher E; Rail J; Turgeon J; Crismon ML
Pharmacotherapy; 1999 Sep; 19(9):1057-63. PubMed ID: 10610012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
